Click here to read the expert reaction to the BMJ article: Click here to read the BMJ article: Science Media Centre University of East London Wegovy(semaglutide) HCP Mounjaro (tirzepatide) HCP To view or add a comment, sign in Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life and few show cardiovascular benefits at one year, finds a new study in The BMJ Greater weight loss was consistently accompanied by higher rates of side effects and treatment discontinuation, which the authors say indicates a clear benefit-harm trade-off
11 In this trial, empagliflozin significantly reduced cardiovascular death by 38% (HR 0.62
It seems, however, that while stimulation of some GLP-1R expressing neuronal populations is responsible for reducing food intake in association with nausea or aversion stimulation of others can lead to food intake reduction via mechanisms independent of nausea (McMahon and Wellman, 1998
Common signs include dark yellow urine, urinating much less than usual, a dry mouth, dizziness when you stand up, and feeling unusually tired or lightheaded
Those who need in-person care or frequent live visits Those who want to use insurance for name-brand GLP-1s Anyone with a history of thyroid cancer, pancreatitis, or significant GI issues
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis was published in The BMJ in January 2024
